about
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenDevelopment and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvantTLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN RoutesCrystal structures of Toxoplasma gondii HGXPRTase reveal the catalytic role of a long flexible loopDevelopment of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responsesA structure-function approach to optimizing TLR4 ligands for human vaccinesA Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.Use of ProteinChip array surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) to identify thymosin beta-4, a differentially secreted protein from lymphoblastoid cell lines.Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.Differential localization of alternatively spliced hypoxanthine-xanthine-guanine phosphoribosyltransferase isoforms in Toxoplasma gondii.A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosisAccounting for adjuvant-induced artifacts in the characterization of vaccine formulations by polyacrylamide gel electrophoresisUse of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons.Upregulated expression of B-cell antigen family tandem repeat proteins by Leishmania amastigotesImmunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer.Biased cellular locations of tandem repeat antigens in African trypanosomes.Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cellsInsight toward early diagnosis of leprosy through analysis of the developing antibody responses of Mycobacterium leprae-infected armadillos.Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.Serological characterizations of tandem repeat proteins for detection of African trypanosome infection in cattle.Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.Mammaglobin: a candidate diagnostic marker for breast cancer.Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.Intracellular Signaling and Desmoglein 2 Shedding Triggered by Human Adenoviruses Ad3, Ad14, and Ad14P1.Sm-p80-based schistosomiasis vaccine mediated epistatic interactions identified potential immune signatures for vaccine efficacy in mice and baboons.Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic.Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor ModelsSelection of antigens and development of prototype tests for point-of-care leprosy diagnosis.Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in miceDevelopment of a schistosomiasis vaccine.Optimized subunit vaccine protects against experimental leishmaniasis.Adjuvants for malaria vaccines.Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons.Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimerRole of adjuvants in modeling the immune response.Protein engineering to target complement evasion in cancer.The science of vaccine adjuvants: advances in TLR4 ligand adjuvants.
P50
Q21089693-E54EAB0B-D89A-416B-AB99-341619819F86Q21091066-8C03FEBA-3C76-4B76-8241-8964203C3F34Q27322386-24E940DE-EFC7-443C-B66C-20F7C3BF0E63Q27733464-36238A44-5585-4AE5-8FF7-E1F5C8DFB280Q28292339-EBAC68F0-DCFD-40E9-A7F1-E06C960D1C47Q28818147-D1F05559-B8CF-4984-A744-5B2CBF1B8990Q30401247-9539A29E-7E80-4AC5-9A69-AAABC7831020Q30956634-2DF0A75A-E811-4B4C-9FD8-4F4EC48FAFAEQ31076192-1D6B628B-50D8-4A42-90D6-83941B1C3B9CQ31158153-D6E68BE2-E8F8-49FD-8939-6BFFDE3EFB13Q33583613-8CC62A7D-BCF5-4AF6-B5F5-CA818F8AB6BAQ33627089-1238AA55-C890-4B1D-A9A2-59E0333E34ADQ33641234-B3ADFA29-5571-4C31-B480-FF1E973333BCQ33684408-FC7D6804-F12F-410E-9A36-A0E6574861F1Q33826124-3EA6491A-79D5-420E-A019-BFF984C44BE5Q34128082-9BAF5B25-634B-4F54-866A-227C3D12238DQ34129623-AEBC80C8-18A2-4386-988C-EEA299D6A1BBQ34590465-202B7556-45A2-4098-9792-47438127AD34Q34735203-C530FC62-0577-4C75-B020-8D2EC97A70F2Q34738846-1BAFE705-2BAA-4CBF-B3A8-66749819DB62Q35439931-E07031DC-1E0E-477B-8293-B42609A87A25Q35577142-C5221556-5CCB-4A4B-8AE0-83D20841A0C8Q35651085-F3F4063C-6BE3-452E-A4D7-B23DBD56C437Q35683590-75415127-6C4C-4B3D-92DB-4F5BA66C6EF1Q36012177-3E06BC52-8C53-45D3-82FC-5DEA8D5288C4Q36208218-60EDC2B5-B966-4780-8C9F-645FD56C8523Q36278786-FD53CEE6-A14A-4224-AF5B-9C6DD2817BA7Q36673736-2BDCAAD5-A091-4F78-A68C-D7649E59C297Q36744857-E703E15D-D9D2-4EA5-B668-3DA6824BFCC5Q36825407-593E181E-D157-47CA-B5B4-7AAD638B66B3Q36933064-A24F1C85-FF10-4E04-A03D-BA894D977065Q37140167-D4956A73-8382-49F4-8D16-62FA451FBFEDQ37350747-FC1FB532-9152-41D9-B904-BAAEEAF59CA1Q37439440-DE1637E5-CC68-4031-9814-5A121F89A53AQ37582428-3E9C5E27-FB6A-47C6-8E16-2A14D28AC436Q37603033-30703B79-2755-4653-B695-B839DEF9914CQ37692880-F1710C14-F128-4718-A439-BCB523F5BCF7Q37803320-84E34C82-4CB8-47C3-9660-22DB56961F89Q38163242-46EC584D-050C-45CA-A53E-B1DBFD581CB1Q38890271-0BA9B5C6-E803-45B8-B350-6AAE361A65F6
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Darrick Carter
@ast
Darrick Carter
@en
Darrick Carter
@es
Darrick Carter
@fr
Darrick Carter
@nl
Darrick Carter
@sl
type
label
Darrick Carter
@ast
Darrick Carter
@en
Darrick Carter
@es
Darrick Carter
@fr
Darrick Carter
@nl
Darrick Carter
@sl
prefLabel
Darrick Carter
@ast
Darrick Carter
@en
Darrick Carter
@es
Darrick Carter
@fr
Darrick Carter
@nl
Darrick Carter
@sl
P1053
N-3304-2016
P106
P1153
55255864000
P21
P214
271153409799141582985
P31
P3829
P496
0000-0001-5901-3402
P734
P7859
lccn-nb2018015423